'Do not Do' Recommendations in Hemophilia.

Q2 Medicine
Hortensia De la Corte-Rodriguez, E Carlos Rodriguez-Merchan, M Teresa Alvarez-Roman, Monica Martin-Salces, Victor Jimenez-Yuste
{"title":"'Do not Do' Recommendations in Hemophilia.","authors":"Hortensia De la Corte-Rodriguez,&nbsp;E Carlos Rodriguez-Merchan,&nbsp;M Teresa Alvarez-Roman,&nbsp;Monica Martin-Salces,&nbsp;Victor Jimenez-Yuste","doi":"10.2174/1871529X20666200305111323","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>It is important to discard those practices that do not add value. As a result, several initiatives have emerged. All of them try to improve patient safety and the use of health resources.</p><p><strong>Purpose: </strong>To present a compendium of \"do not do recommendations\" in the context of hemophilia.</p><p><strong>Methods: </strong>A review of the literature and current clinical guidelines has been made, based on the best evidence available to date.</p><p><strong>Results: </strong>The following 13 recommendations stand out: 1) Do not delay the administration of factor after trauma; 2) do not use fresh frozen plasma or cryoprecipitate; 3) do not use desmopressin in case of hematuria; 4) do not change the product in the first 50 prophylaxis exposures; 5) do not interrupt immunotolerance; 6) do not administer aspirin or NSAIDs; 7) do not administer intramuscular injections; 8) do not do routine radiographs of the joint in case of acute hemarthrosis; 9) Do not apply closed casts for fractures; 10) do not discourage the performance of physical activities; 11) do not deny surgery to a patient with an inhibitor; 12) do not perform instrumental deliveries in fetuses with hemophilia; 13) do not use factor IX (FIX) in patients with hemophilia B with inhibitor and a history of anaphylaxis after administration of FIX.</p><p><strong>Conclusion: </strong>The information mentioned previously can be useful in the management of hemophilia, from different levels of care. As far as we know, this is the first initiative of this type regarding hemophilia.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"20 3","pages":"168-174"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular and Hematological Disorders - Drug Targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871529X20666200305111323","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2

Abstract

Background: It is important to discard those practices that do not add value. As a result, several initiatives have emerged. All of them try to improve patient safety and the use of health resources.

Purpose: To present a compendium of "do not do recommendations" in the context of hemophilia.

Methods: A review of the literature and current clinical guidelines has been made, based on the best evidence available to date.

Results: The following 13 recommendations stand out: 1) Do not delay the administration of factor after trauma; 2) do not use fresh frozen plasma or cryoprecipitate; 3) do not use desmopressin in case of hematuria; 4) do not change the product in the first 50 prophylaxis exposures; 5) do not interrupt immunotolerance; 6) do not administer aspirin or NSAIDs; 7) do not administer intramuscular injections; 8) do not do routine radiographs of the joint in case of acute hemarthrosis; 9) Do not apply closed casts for fractures; 10) do not discourage the performance of physical activities; 11) do not deny surgery to a patient with an inhibitor; 12) do not perform instrumental deliveries in fetuses with hemophilia; 13) do not use factor IX (FIX) in patients with hemophilia B with inhibitor and a history of anaphylaxis after administration of FIX.

Conclusion: The information mentioned previously can be useful in the management of hemophilia, from different levels of care. As far as we know, this is the first initiative of this type regarding hemophilia.

血友病的“不做”建议。
背景:抛弃那些不能增加价值的实践是很重要的。因此,出现了几项倡议。他们都试图改善病人的安全和卫生资源的使用。目的:在血友病的背景下提出“不做建议”的纲要。方法:回顾文献和目前的临床指南,根据迄今为止最好的证据。结果:突出以下13条建议:1)创伤后不要延误因子的给药;2)不要使用新鲜的冷冻血浆或低温沉淀物;3)血尿时不要使用去氨加压素;4)在前50次预防暴露中不要更换产品;5)不中断免疫耐受;6)不要服用阿司匹林或非甾体抗炎药;7)不要进行肌肉注射;8)急性关节血肿不做关节常规x线片;9)骨折不要使用闭合石膏;10)不妨碍体育活动的进行;11)不拒绝对使用抑制剂的患者进行手术;12)血友病胎儿不要使用器械分娩;13) B型血友病患者在使用FIX后,如果有抑制剂且有过敏史,则不要使用IX因子(FIX)。结论:上述信息可用于血友病的管理,从不同的护理水平。据我们所知,这是针对血友病的首个此类倡议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cardiovascular and Hematological Disorders - Drug Targets
Cardiovascular and Hematological Disorders - Drug Targets Medicine-Cardiology and Cardiovascular Medicine
CiteScore
1.90
自引率
0.00%
发文量
36
期刊介绍: Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信